Clinical Trials Directory

Trials / Completed

CompletedNCT01109680

A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
8 (estimated)
Sponsor
Merz Pharmaceuticals GmbH · Industry
Sex
Male
Age
55 Years – 65 Years
Healthy volunteers
Accepted

Summary

A Single Center, Open-Label Study to quantify metabolites of \[14C\]-Neramexane in plasma and urine in Healthy Male Subjects

Conditions

Interventions

TypeNameDescription
DRUGNeramexaneMultiple dose Neramexane followed by single dose 14C Neramexane

Timeline

Start date
2010-04-01
Primary completion
2010-06-01
Completion
2010-06-01
First posted
2010-04-23
Last updated
2011-02-08

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01109680. Inclusion in this directory is not an endorsement.

A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjec (NCT01109680) · Clinical Trials Directory